Kura Oncology launches Caspian Therapeutics, targets clinical proof-of-concept for diabetes drug KO-7246 after USD 50 million financing
Reuters2026/09/09 11:04- Kura Oncology launched Caspian Therapeutics with USD 50 million financing to advance KO-7246, a menin inhibitor for diabetes.
- Preclinical results were selected for future oral presentation at EASD on Sept. 29, 2026.
- Animal and human islet studies showed improved insulin production and glycemic control, suggesting potential durable restoration of β-cell function.
- Funding targets IND-enabling work and initial clinical proof-of-concept, while Kura retains about half ownership on a fully diluted basis.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Colgate-Palmolive (CL.US) plans to sell part of its personal care brands, with a total transaction amount possibly exceeding 1.1 billions USD.
According to sources familiar with the matter, Colgate is exploring the sale of some of its mass-market personal care brands. The company currently plans to divest only a few brands within its personal care business, and the combined sale price may exceed 1 billion dollars.
EdiliziAcrobatica announces shareholder meeting notice
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.
Crypto prices
More
